Introduction
Endothelial cells are known as strong inhibitors of intravascular thrombosis 1) . It is well known that endothelial cells release many bioactive substances known to inhibit local activation of platelets, such as nitric oxide (NO) 2, 3) , prostaglandin (PG)-I2 [4] [5] [6] , tissue type plasminogen activators (t-PA) 7) etc. In clinical els [13] [14] [15] [16] [17] . These stimulations are presumed to produce free radicals to injure endothelial cell function [18] [19] [20] ; however, the detailed physiological mechanism resulting in formation of arterial occlusive thrombi is yet to be clarified.
In the present study, we investigated morphological characteristics of endothelial cells under conditions where FeCl3-induced injury was applied to mice cremastric arteries by the use of a newly-developed fluorescent imaging system. We also investigated thrombus formation at the site of endothelial injury by the newly-developed real time 3D imaging system. We have shown here the accumulation of platelets at the site of FeCl3-induced injury even in the physical presence of endothelial cells. These initially accumulated platelets grew 3-dimensionally way even under conditions of arterial blood flow forming arterial occlusive thrombi, despite the presence of endothelial cells. Pre-treatment with the common antiplatelet agent clopidogrel significantly prolonged the occlusion time of cremastric artery while the same amount of aspirin had modest inhibiting effects. Similar inhibiting effects were reproduced in flow chamber experiments deficient in endothelial cells, suggesting similarity between the thrombi formed on immobilized collagen under controlled blood flow conditions and in vivo arterial thrombus formation.
Methods

FeCl3-induced Endothelial Injury in Mice Cremasteric Arteries
Male ICR mice (CLEA Japan, Inc., Tokyo, Japan), aged from 10 to 11 weeks, were housed 4 or 5 per cage in acclimatized colony rooms on a natural lightdark cycle, with food and water continuously available, for at least 1 week before experimental use. Experimental mice were pre-anesthetized by intraperitoneal injection of ketamine, xylazine and atropine sulfate, and then anesthetized more deeply with intravenous injection of nembutal through the jugular vein. The cremaster muscle of each experimental mouse was prepared on a glass plate rich in saline 5 minutes before starting the experiments. Newlydeveloped intra-vital real time-3D imaging of platelet thrombi, described later, was performed. Endothelial cells were rendered fluorescent by FITC-labeled isolectin B4, a murine-specific endothelial cell marker. One hundred microliters of 0.1% rhodamine 6G containing saline was administered additionally to render platelets and leukocytes fluorescent. To initiate platelet thrombus formation, endothelial injury was induced to the cremasteric artery by applying a 0.2 mm diame- 
Pretreatment by Antiplatelet Agents
For drug intervention experiments, animals are pretreated either by aspirin or clopidogrel at doses of 1, 10, and 100 mg/kg 4 hours before starting FeCl3 injury. Indeed, each drug was administered orally. For ex vivo experiments with flow chambers, a 1 mL blood sanple was obtained directly from the heart of each experimental mouse.
3D Imaging of Thrombi
The 3D images of thrombi developed at the site of FeCl3-induced endothelial damage were detected in real time with our newly-developed real-time 3D imaging system using ultra-fast confocal microscopy equipped with a piezo-motor control unit 21) . 3D growth of thrombi was continuously recorded with a personal computer (PowerMac, Apple, Co., USA). Time to complete occlusion of cremasteric arteries by thrombi was also measured in each experiment.
In Vitro Experiments with Flow Chamber
The blood samples obtained from mice were anticoagulated by addition of a specific thrombin inhibitor, argatroban, up to the final concentration of 100 M. Platelet interaction with immobilized von Willebrand factor and the thrombi formed on the collagen fibrils during five-minute perfusion of blood at a wall shear rate of 1,500 s 1 were visualized by the same confocal microscopy. The details of our experimental methods have been published previously [21] [22] [23] .
Statistical Analyses
All numerical data are expressed as the mean SEM, unless otherwise specified. The effect of various concentrations of aspirin and clopidogrel on the growth of platelet thrombi was tested by one-way analysis of variance (ANOVA). Differences between two groups of data were evaluated by the NewmanKeuls test; p values 0.05 were considered significant.
Results
Structural Changes of Endothelial Cells Induced by FeCl3
In the controls, endothelial cells were tightly covered over mice cremastric arteries, preventing blood cell interaction (Fig. 1) . The shape of endothelial cells became round and platelets started to adhere to the connection sites between endothelial cells immediately after application of FeCl3 stimulation. Platelet thrombi continued to grow not only in the xy-direction, but also in the z-direction in the absence of pre-treament with clopidogrel or aspirin (Fig. 2) . Thrombi became large enough to occlude cremasteric arteries 10.6 7.5 minutes after initiation of FeCl3 application in the controls (Fig. 3) . During the process of thrombus growth, loose parts of thrombi detached to form distal emboli. Endothelial cells are physically present even when cremasteric arteries are completely occluded by thrombi (Fig. 4) .
Effects of Aspirin and Clopidogrel on the Growth of Thrombi at Sites of FeCl3-Induced Injury
Neither aspirin nor clopidogrel influenced structural changes of endothelial cells after application of FeCl3 (data not shown); however, clopidogrel pretreatment significantly reduced the 3D growth of platelet thrombi and prolonged vascular occlusion time (Fig. 2, 3) . Indeed, mean occlusion time was significantly prolonged from 10.6 7.5 minutes in the absence of drug addition to 64.6 25.3 minutes after pre-treatment with 100 mg/kg clopidogrel (Fig. 3) . Aspirin, on the other hand, showed only modest inhibiting effects both at the lowest and highest concentrations tested (Fig. 2, 3) .
A similar inhibiting effect of clopidogrel was reproduced in thrombus growth on collagen fibrils in flow chamber experiments (Fig. 5) (at a wall shear rate of 1,500 s 1 ). Single platelet movement on the immobilized von Willebrand factor was detected and quantified as described previously (Fig. 6) 
23)
.
Discussion
Our experimental findings demonstrate platelet adhesion on endothelial cells functionally injured by the effects of FeCl3. We have also demonstrated that even arterial occlusive thrombi developed at the site of FeCl3-induced injured endothelial cells are physically present. Similarly to a previous publication 24) , arterial occlusive thrombus formation was markedly inhibited in mice pre-treated with clopidogrel. The inhibiting effects of aspirin in an animal model of thrombosis varied in the previous publication. Similar to the previous FeCl3-induced thrombus model 25) , but unlike arterial thrombus models induced by laser light or balloon injury 26, 27) , the inhibiting effect of aspirin was only modest in our study. Similar results were reproduced in ex vivo perfusion experiments on immobilized collagen fibrils under controlled blood flow conditions.
The most important role of circulating platelets is accumulation at the site of vascular damage to prevent bleeding. It is reasonable that occlusive thrombus formation started at the site of atheroma rupture because platelets are known to accumulate on the exposed subendothelial matrix of collagen, von Willebrand factor, fibronectin, etc 9, [28] [29] [30] [31] . Our experimental results provide insight into understanding the mechanism of myocardial infarction in the absence of atheroma rupture. We have shown here that both platelet adhesion and occlusive thrombus formation can be induced at the site of functionally injured endothelium by exposure to FeCl3. We also demonstrate the physical presence of endothelial cells at a site where arterial occlusive thrombi were formed.
Previously published clinical trials demonstrated significant, but not markedly strong preventive effects of clopidogrel as compared to those of aspirin 32) ; however, in our experimental condition, there were substantial differences in the effects between aspirin and clopidogrel. As previously demonstrated, platelet ADP receptor P2Y12 plays a crucial role in maintaining the stability of platelet thrombi under blood flow conditions 21, 23, 33, 34) , while the cyclo-oxygenase pathway, which was blocked by aspirin, does not play a major Experiments were conducted similar to as described in the legend for Fig. 2 . Time between starting FeCl3 stimulation to complete occlusion of cremasteric arteries by thrombi was measured. Each bar represents the mean occlusion time of 8 replicated experiments while the error bar demonstrates standard errors. : indicates that the mean value is significantly different from the control. ASA represent pretreatment by aspirin, while CLO represents pretreatment by clopidogrel. : indicate that the p-value of the difference is 0.01. role in platelet thrombus formation under blood flow conditions 35, 36) . We speculate that the effects of aspirin in preventing of myocardial infarction and stroke are mostly due to inhibition of the local release of thromboxane A2, resulting in disturbance of the microcirculation 37) . We speculate that blockage of the ADP receptor plays a more important role in the formation of arterial occlusive thrombi in a mouse model. Our results suggest that animal models, such as the one shown here, are effective for screening clinically effective antiplatet agents such as clopidogrel but it is important to note that the acute thrombotic animal model may not represent all aspects of atherothrombotic disease in humans, as indicated by a failure to demonstrate inhibiting effects of the strongly clinically supported antiplatelet agent, aspirin, in our experimental setting.
It is a well known that a large-scale, prospective, randomized double-blind clinical trial is necessary to demonstrate the efficacy and safety of newly-developed antithrombotic agents. As demonstrated by the experience with orally administered anti-GP b/ a agents, clinically relevant efficacy is difficult to predict not only with in vitro testing, such as platelet aggregation, but even with in vivo animal experiments 38) . The similarity of the results with aspirin and clopidogrel in in vivo animal models and ex vivo flow chamber experiments requiring anticoagulant agents to maintain the fluidity of blood throughout the experiments may support the notion that ex vivo perfusion experiments are in agreement with the results of in vivo animal experiments. Nevertheless, a better platelet functional assay which can predict the outcome of clinical trials is awaited. Whole blood samples obtained from experimental mice were perfused on immobilized type collagen at a wall shear rate of 1,500 s 1 for 5 minutes. Thrombi were detected by a 3-dimensional imaging technique using an ultra-fast laser confocal microscope equipped with a piezo-motor control unit, as described previously. Upper panels (A) show projection images at 0 degrees along the x-axis corresponding to the projection from the top of the thrombi, while the lower panels (B) and (C) show the projection images at 45 and 90 degrees along the x-axis. The results with aspirin-treated blood were similar to control results. Experiments were conducted similar to as described in the legend for ing fees from Eisai, Sanofi-Aventis, Daiichi-Sankyo, GlaxoSmithKline, Bristol-Myers Scribb, Otsuka, Bayer, Schering-Plough, Takeda, Astellas, AstraZeneca, Novartis and Kowa. Shinya Goto also received research grants from Pfizer, Ono, Eisai, Otsuka, Daiichi-Sankyo, Sanofi-Aventis, Takeda and Astellas within the last 3 years. Hideyuki Ishida has also received research grants from Eisai, Taiho and Chugai within the last 3 years.
